Towards Healthcare
Meloxicam Market to Reach USD 12.23 Bn by 2034

Meloxicam Market Growth Redefining Anti-Inflammatory Solutions

According to forecasts, the global meloxicam market will grow from USD 7.62 billion in 2024 to USD 12.23 billion by 2034, with an expected CAGR of 4.84%. The market is growing due to the increasing prevalence of inflammatory and pain-related conditions, along with rising demand for safe, effective NSAID therapies. In North America, the market dominates because of high healthcare awareness, extensive prescription practices, and strong adoption of advanced pain management treatment.

  • Insight Code: 6256
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

The meloxicam market holds a valuation of USD 7.99 billion as of 2025, and will expand to USD 12.23 billion by 2034, achieving a CAGR of 4.84% between 2024 and 2034.

North America is currently leading the meloxicam market due to advanced healthcare facilities, strong regulatory support, and high adoption of innovative pain management therapies.

Cipla Ltd., Dr. Reddy Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Ltd., Aurobindo Pharma Ltd., Torrent Pharmaceuticals Ltd. 

It is prescribed for adults with inflammatory or pain-related conditions. Pediatric use is limited and depends on a doctor guidance.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.